Cost-Effectiveness of Triple Therapy Versus Etanercept Plus Methotrexate in Early Aggressive Rheumatoid Arthritis

Arthritis Care and Research

Volumn 68, Issue 12, 2016, Pages 1751-1757

  Jalal, Hawre ^a   O'Dell, James R ^b   Bridges, S Louis ^c   Cofield, Stacey ^c   Curtis, Jeffrey R ^c   Mikuls, Ted R ^b,d   Moreland, Larry W ^a   Michaud, Kaleb ^b,e  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^e NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; HYDROXYCHLOROQUINE; METHOTREXATE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR;

ADULT; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG COST; HUMAN; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; ARTHRITIS, RHEUMATOID; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEALTH CARE COST; MALE; MARKOV CHAIN; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL FACTORS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; ETANERCEPT; FEMALE; HEALTH CARE COSTS; HUMANS; HYDROXYCHLOROQUINE; MALE; MARKOV CHAINS; METHOTREXATE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; SULFASALAZINE; TIME FACTORS;

EID: 84992409146     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22895     Document Type: Article

References (22)

1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64:625–39.
2. US pharmaceutical sales: Q4 2013. 2014. URL: http://www.drugs.com/stats/top100/sales.
3. Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St.Clair EW, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012;64:2824–35.
4. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762–84.
5. Arias E. United States life tables, 2006. Natl Vital Stat Rep 2010;58:1–40.
6. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530–42.
7. Van der Velde G, Pham B, Machado M, Ieraci L, Witteman W, Bombardier C, et al. Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review. Arthritis Care Res (Hoboken) 2011;63:65–78.
8. Shahouri SH, Michaud K, Mikuls TR, Caplan L, Shaver TS, Anderson JD, et al. Remission of rheumatoid arthritis in clinical practice: application of the American College of Rheumatology/European League Against Rheumatism 2011 remission criteria. Arthritis Rheum 2011;63:3204–15.
9. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all “quality-adjusted life years” are equal. J Clin Epidemiol 2007;60:616–24.
10. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750–62.
11. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316–27.
12. Pedro S, Wolfe F, Jalal H, Michaud K. Discontinuation rates in patients with RA of triple disease modifying antirheumatic therapy [abstract]. Arthritis Rheum 2013;65 Suppl:S450.
13. Ramiro S, Wolfe F, Harrison DJ, Joseph GJ, Collier DH, van der Heijde D, et al. Comparison of discontinuation rates by biologic since 1998 in US patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2012;64 Suppl:S216.
14. US Department of Labor. Bureau of Labor Statistics. Consumer price index. URL: http://www.bls.gov/cpi.
15. Bansback N, Phibbs C, Sun H, O'Dell J, Brophy M, Keystone E, et al. Cost-effectiveness of adding etanercept vs. sulfasalazine and hydroxychloroquine to methotrexate therapy: a randomized noninferiority trial [abstract]. Arthritis Rheumatol 2014;66 Suppl:S1214.
16. Eriksson JK, Karlsson JA, Bratt J, Petersson IF, van Vollenhoven RF, Ernestam S, et al. Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial. Ann Rheum Dis 2015;74:1094–101.
17. Jalal H, Michaud K, Choi H, Rho YH, Kuntz K. Are biologics cost-effective? Analysis based on real-life rheumatoid arthritis patients [abstract]. Arthritis Rheum 2011;63 Suppl:S1011.
18. Bonafede M, Johnson BH, Tang DH, Shah N, Harrison DJ, Collier DH. Etanercept-methotrexate combination therapy initiators have greater adherence and persistence than triple therapy initiators with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2015;67:1656–63.
19. Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2015. E-pub ahead of print.
20. Brodszky V, Baji P, Balogh O, Pentek M. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six central and eastern European countries. Euro J Health Econ 2014;15 Suppl 1:S65–71.
21. Reuters T. Red book: pharmacy's fundamental reference. Montvale (NJ): PDR Network; 2010.
22. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses: panel on cost-effectiveness in health and medicine. JAMA 1996;276:1339–41.